Endocrine Abstracts

Introduction: Hypertension (HTN) is a major cardiovascular (CV) risk factor and independent predictor of the increased mortality in patients with acromegaly. Surgical cure of acromegaly is associated with improvement in blood pressure (BP) levels, however little is known on the effect of pegvisomant (PEGV) treatment on HTN.Methods/design: ACROSTUDY is an open-label, international, prospective, non-interventional study monitoring the long-term safety of P...

Context: Transsphenoidal surgery (TSS) is the primary treatment of choice in acromegaly. It is important to identify patients in whom surgical cure is not attainable at an early stage, both to inform patients on expected treatment outcome and to select those who are more likely to need additional therapy.Objective: To identify predictors for remission and relapse after TSS in acromegaly.Design: Retrospective study in three large te...

Background: Testosterone (T) in a hydroalcoholic gel is commonly prescribed as androgen replacement therapy and may not be accompanied by peaks and troughs of serum T levels as seen in T-injectables. We assessed in 17 subjects the differences in serum testosterone (sT) and free T (fT) levels during four different application periods.Methods: Patients where on daily 50 mg Androgel®, for 7 consecutive days in each cycle, on day 8 serum was ...

Background: The response to first-generation long-acting somatostatin analogues (LA-SSA) treatment in acromegaly depends on the expression of the somatostatin receptor (SSTR) subtypes. In contrast to octreotide and lanreotide which preferentially bind to SSTR2, pasireotide targets multiple SSTRs, with the highest binding affinity for SSTR5. It has previously been suggested that SSTR5 expression could predict the response to pasireotide LAR (PAS-LAR) treatment in acromegaly.</p...

Introduction: Craniopharyngiomas are benign tumors in the suprasellar region that have encouraging survival rates between 77-93%. Unfortunately, long-term sequelae are frequent, resulting in excessive endocrine and metabolic morbidity, including premature cardiovascular disease and reduced bone health.Objective: To determine the prevalence of unfavorable body composition and low bone mineral density (BMD) in patients with craniopharyngioma.<p class="...

Background: Patients with acromegaly without detectable pituitary adenoma on conventional MRI are often excluded from adenomectomy due to inherent challenges of precise surgical planning, significantly limiting both their therapeutic options and chances of curation. Previous research showed that O-(2-[18F]fluoroethyl)-L-tyrosine ([18F]FET) PET-MRI is an accurate diagnostic tool to detect small functional pituitary adenomas (1). The present study aims to investigate the diagnos...

Objective: Craniopharyngioma (CP) is a benign tumor of the sellar/hypothalamic region. It is associated with endocrinopathies, which may potentially impair bone health. Our objective was to determine bone health status in CP patients.Methods: In this retrospective study, Dutch/Swedish CP patients were included if data was available on fractures, bone mineral density (BMD) (T/Z-score), or final height (age >18 years). Data is presented as mean±<s...

Background: Previous studies indicate that PAS-LAR can achieve control of insulin-like growth factor I (IGF-I) levels and may reduce tumor size, however a subset of acromegaly patients responds poorly. T2-signal intensity, somatostatin receptor (SST) subtype 2 and 5 expression, and the response to first-generation somatostatin receptor ligands (SRLs) are recognized predictors of therapy response. Valid prediction of the response to PAS-LAR can alter treatment stratification.</...

Introduction: Craniopharyngioma (CP) is a benign tumor of the sellar/hypothalamic region. It is associated with excess mortality, obesity and endocrinopathies. These endocrinopathies may influence bone health, and increase the risk of fractures.Methods: In this retrospective study, Dutch/Swedish patients with CP were included if data was available on final height (at age >18 years) or DXA-scan results. Information from the first and last DXA-scans we...

Background: Prolactinomas are the most frequent secreting pituitary adenomas encountered in the clinical setting. Cabergoline is considered the mainstay medical treatment and transsphenoidal surgery (TSS) is recommended for patients that are medically resistant to dopamine agonist therapy. Resistance to dopamine agonists is commonly defined as failure to normalize prolactin and less than 50% decrease in tumor diameter at a maximal labeled dose of 2.0 mg/week. Pasireotide LAR (...